Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacology and Therapeutics

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2016.06.010PMID 27373504PMCID PMC5035606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

  2016cited by this paper
• Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

  2016cited by this paper
• Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

  2016cited by this paper
• A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

  2016influential reference
• Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

  2016cited by this paper
• Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

  2016cited by this paper
• PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

  2016influential reference
• Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.

  2016cited by this paper
• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

  2016cited by this paper
• Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.

  2016cited by this paper
• IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.

  2016cited by this paper
• Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

  2015cited by this paper
• T cell exclusion, immune privilege, and the tumor microenvironment

  2015cited by this paper
• Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

  2015influential reference
• T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.

  2015cited by this paper
• Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies

  2015cited by this paper
• Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases

  2015influential reference
• CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors

  2015cited by this paper
• 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors

  2015cited by this paper
• A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

  2015cited by this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015influential reference
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes

  2015cited by this paper
• Targeting YAP-dependent MDSC infiltration impairs tumor progression

  2015cited by this paper
• Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.

  2015cited by this paper
• IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA

  2015influential reference
• Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

  2015cited by this paper
• Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers

  2015cited by this paper
• Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

  2015cited by this paper
• Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.

  2015cited by this paper
• Exclusion of T Cells From Pancreatic Carcinomas in Mice is Regulated by Ly6C low F4/80 + Extra-tumor Macrophages

  2015cited by this paper
• IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

  2015cited by this paper
• Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors

  2014cited by this paper
• Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma

  2014cited by this paper
• Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients

  2014cited by this paper
• Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

  2014influential reference
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity

  2014cited by this paper
• Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer

  2014cited by this paper
• Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

  2013cited by this paper
• Harnessing the antitumor potential of macrophages for cancer immunotherapy

  2013cited by this paper
• Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

  2013cited by this paper
• The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

  2013cited by this paper
• Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

  2013cited by this paper
• Vascular normalization as an emerging strategy to enhance cancer immunotherapy.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

  2013cited by this paper
• EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

  2013cited by this paper
• CSF-1R inhibition alters macrophage polarization and blocks glioma progression

  2013cited by this paper
• Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

  2013cited by this paper
• Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

  2013cited by this paper
• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  2013influential reference
• A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

  2013cited by this paper
• Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

  2013cited by this paper
• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

  2013cited by this paper
• Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

  2013cited by this paper
• Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

  2013cited by this paper
• Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia

  2013cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013influential reference
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

  2012cited by this paper
• Molecular Pathways Molecular Pathways : Hypoxia Response in Immune Cells Fighting or Promoting Cancer

  2012cited by this paper
• Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF

  2012cited by this paper
• The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011influential reference
• Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

  2011influential reference
• CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis

  2011cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011cited by this paper
• Chemokines and cancer: a fatal attraction.

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

  2011cited by this paper
• Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

  2010cited by this paper
• Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence

  2010cited by this paper
• Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

  2010cited by this paper
• An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy.

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010influential reference
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• CAR mechanics: driving T cells into the MUC of cancer.

  2009cited by this paper
• An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

  2009cited by this paper
• Creating immune privilege: active local suppression that benefits friends, but protects foes

  2008cited by this paper
• Creating immune privilege: active local suppression that benefits friends, but protects foes

  2008cited by this paper
• A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer

  2008cited by this paper
• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

  2008cited by this paper
• Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane1

  2008cited by this paper
• Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

  2008cited by this paper
• Adoptive cell transfer: a clinical path to effective cancer immunotherapy

  2008cited by this paper
• Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment

  2007cited by this paper
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

  2007cited by this paper
• Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

  2007cited by this paper
• Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

  2006cited by this paper

• Targeting GPA33 with CAR-macrophages: a novel immunotherapeutic approach for colorectal cancer.

  2026cites this paper
• Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer

  2025cites this paper
• A Review- Nanoparticle-Mediated Modulation of Tumor Hypoxia: Enhancing Cancer Immunotherapy and Therapeutic Efficacy

  2025cites this paper
• T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer

  2025cites this paper
• Geometric immunosuppression in CAR T-cell treatment: Insights from mathematical modeling

  2025cites this paper
• Adoptive T Cell Therapy Targeting MAGE-A4

  2025cites this paper
• Classic versus innovative strategies for immuno-therapy in pancreatic cancer.

  2025cites this paper
• Targeting PGE2-IL-1β axis to impact future treatments for pancreatic ductal adenocarcinoma and its precursors

  2025cites this paper
• Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

  2025cites this paper
• Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma

  2025cites this paper
• Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.

  2025cites this paper
• Current status of chimeric antigen receptor T cell therapy and its exhaustion mechanism.

  2025cites this paper
• Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years

  2025cites this paper
• Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering

  2024cites this paper
• Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy

  2024cites this paper
• CAR T cell infiltration and cytotoxic killing within the core of 3D breast cancer spheroids under the control of antigen sensing in microwell arrays

  2024cites this paper
• Engineering M1 macrophages with targeting aptamers for enhanced adoptive immunotherapy by modifying the cell surface.

  2024cites this paper
• Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.

  2024cites this paper
• Car T Cells in Solid Tumors: Overcoming Obstacles

  2024cites this paper
• Overview of tumor immunotherapy based on approved drugs.

  2024cites this paper
• Challenges of Anti-Mesothelin CAR-T-Cell Therapy

  2023cites this paper
• Navigating Tumour Microenvironment and Wnt Signalling Crosstalk: Implications for Advanced Cancer Therapeutics

  2023cites this paper
• Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy

  2023cites this paper
• The application of HER2 and CD47 CAR-macrophage in ovarian cancer

  2023cites this paper
• Intelligent tunable CAR-T cell therapy leads the new trend

  2023cites this paper
• Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC.

  2023cites this paper
• Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer

  2023cites this paper
• Promise and Challenges of T Cell Immunotherapy for Osteosarcoma

  2023cites this paper
• Manufacturing innovation to drive down cell therapy costs.

  2023cites this paper
• Advancements in Systemic Therapy for Pancreatic Cancer.

  2023cites this paper
• Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors

  2023cites this paper
• Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma

  2023cites this paper
• Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

  2022cites this paper
• Functional Characterization and Development of Novel Human Kinase Insert Domain Receptor Chimeric Antigen Receptor T-cells for Immunotherapy of Non-Small Cell Lung Cancer.

  2022cites this paper
• From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer

  2022cites this paper
• In-situ scalable manufacturing of Epstein–Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA)

  2022cites this paper
• Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

  2022cites this paper
• Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma

  2022cites this paper
• Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma.

  2022cites this paper
• Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.

  2022cites this paper
• Strategies for manufacturing cell therapy products aligned with patient needs.

  2022cites this paper
• Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

  2022cites this paper
• Cord-Blood-Derived Professional Antigen-Presenting Cells: Functions and Applications in Current and Prospective Cell Therapies

  2021cites this paper
• Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.

  2021cites this paper
• Macrophages as a “weapon” in anticancer cellular immunotherapy

  2021cites this paper
• The biological underpinnings of therapeutic resistance in pancreatic cancer

  2021cites this paper
• Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release

  2021cites this paper
• New intratumoral immunotherapeutic approaches to inhibit the tumor growth and metastasis in breast cancer

  2021cites this paper
• Arming Immune Cell Therapeutics with Polymeric Prodrugs

  2021cites this paper
• Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors

  2021cites this paper
• Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.

  2021cites this paper
• From antibodies to living drugs: Quo vadis cancer immunotherapy?

  2021cites this paper
• Immunotherapy Updates in Advanced Hepatocellular Carcinoma

  2021cites this paper
• Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids

  2021cites this paper
• Macrophages as a Double-Edged Weapon: The Use of Macrophages in Cancer Immunotherapy and Understanding the Cross-Talk Between Macrophages and Cancer

  2021cites this paper
• Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.

  2020cites this paper
• Human chimeric antigen receptor macrophages for cancer immunotherapy

  2020cites this paper
• Biomarkers for Immunotherapy of Cancer: Methods and Protocols

  2020influential citation
• HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.

  2020cites this paper
• The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.

  2020cites this paper
• Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells

  2020cites this paper
• CAR T‑cell therapy for gastric cancer: Potential and perspective (Review).

  2020cites this paper
• Advances in engineering local drug delivery systems for cancer immunotherapy.

  2020cites this paper
• Advances in living cell-based anticancer therapeutics.

  2020cites this paper
• Enhancement of the antitumor effect of HER2‐directed CAR‐T cells through blocking epithelial‐mesenchymal transition in tumor cells

  2020cites this paper
• Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

  2020cites this paper
• Challenges and potential solutions in cellular immunotherapy

  2020cites this paper
• Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion

  2020cites this paper
• ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

  2020cites this paper
• Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review

  2020cites this paper
• Osteosarcoma: A comprehensive review of management and treatment strategies.

  2020cites this paper
• Tumor-macrophage crosstalk: how to listen.

  2020cites this paper
• Impact of drugs targeting tumor metabolism on CD8 T cell effector function

  2020cites this paper
• Advances in the study of CAR-T in digestive system malignancies

  2020cites this paper
• Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

  2019cites this paper
• Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells

  2019cites this paper
• Evaluating CAR‐T Cell Therapy in a Hypoxic 3D Tumor Model

  2019cites this paper
• Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment

  2019cites this paper
• Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.

  2019cites this paper
• Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys

  2019cites this paper
• Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

  2019cites this paper
• Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

  2019cites this paper
• Immunotherapy of pancreatic cancer.

  2019cites this paper
• Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors

  2019cites this paper
• Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma

  2019cites this paper
• Co-expression of PD-L1 Antibodies Enhances the Anti-Tumor Efficacy of Chimeric Antigen Receptor T Cells

  2019cites this paper
• PiggyBac-modified CD19-expressing 4T1 cell line for the evaluation of CAR construct.

  2019cites this paper
• Bispecific antibody based therapeutics: Strengths and challenges.

  2018cites this paper
• Cell therapy products: focus on issues with manufacturing and quality control of chimeric antigen receptor T‐cell therapies

  2018cites this paper
• Analysis of in vitro activity of PSCA-specific CARs in the context of human NK cell line YT

  2018cites this paper
• CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success

  2018cites this paper
• Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives

  2018cites this paper
• mRNA as novel technology for passive immunotherapy

  2018cites this paper
• Strategies to Address Chimeric Antigen Receptor Tonic Signaling

  2018cites this paper
• Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model

  2018influential citation
• Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

  2018cites this paper
• Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy

  2018cites this paper
• Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

  2018cites this paper
• Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

  2018cites this paper
• Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

  2018cites this paper